RCM
TLSI icon

Radcliffe Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Radcliffe Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-466,487
Closed -$4.63M – 905
2022
Q3 		$4.63M Buy
466,487
+50,400
+12% +$499K 0.11% 305
2022
Q2 		$4.1M Buy
416,087
+2,400
+0.6% +$23.6K 0.09% 353
2022
Q1 		$4.05M Hold
413,687
– – 0.09% 329
2021
Q4 		$4.09M Hold
413,687
– – 0.11% 255
2021
Q3 		$4.11M Sell
413,687
-897
-0.2% -$8.78K 0.12% 224
2021
Q2 		$4.02M Hold
414,584
– – 0.13% 236
2021
Q1 		$4M Buy
+414,584
New +$4.2M 0.16% 228

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Radcliffe Capital Management's TLSI Position: Q4 2022 in Review

Radcliffe Capital Management sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 466,487 shares — an estimated $4.63M sold.

Radcliffe Capital Management first reported a position in TLSI in Q1 2021 and held it in 7 quarters. The position peaked at $4.63M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Radcliffe Capital Management reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Radcliffe Capital Management sold 466,487 TriSalus Life Sciences shares in Q4 2022, an estimated $4.63M.
  • Radcliffe Capital Management first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 7 quarters.
  • Radcliffe Capital Management's TriSalus Life Sciences position peaked at $4.63M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Radcliffe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.